Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KLK7 | P49862 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 3/20 | 0.31 |
| ▸ | DRD4 | P21917 | 3/20 | 0.31 |
| ▸ | DRD3 | P35462 | 3/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13067194 | 0.88 | PRKCG (0.38) | MGLLMAPT | |
| SCHEMBL4612086 | 0.87 | MAPT (0.39) | MGLLLMNAMAPTPOLB | |
| SCHEMBL2083953 | 0.83 | CA12 (0.39) | LMNAMAPTHPGD | |
| SCHEMBL9869830 | 0.81 | HTR6 (0.33) | LMNAMAPTHPGDPOLBHSD11B1 | |
| SCHEMBL2747320 | 0.80 | HSD11B1 (0.46) | LMNAHSD11B1FFAR4 | |
| SCHEMBL9870440 | 0.78 | L3MBTL1 (0.34) | LMNAMAPTHPGDHSD11B1KLK7 | |
| SCHEMBL2085855 | 0.78 | HSD11B1 (0.34) | LMNAHSD11B1CCR5 | |
| SCHEMBL4686518 | 0.76 | OPRM1 (0.39) | LMNAMAPTNPSR1 | |
| SCHEMBL13067135 | 0.74 | HSD11B1 (0.34) | HSD11B1FFAR4HDAC6CCR5 | |
| SCHEMBL4688998 | 0.73 | GRIN1 (0.36) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178665-B2 | Process for the production of ezetimibe and intermediates used in this process | RICHTER GEDEON NYRT. (HU) | 2012-05-15 | — | — | US | disclosed |
| US-8178665-B2 | Process for the production of ezetimibe and intermediates used in this process | RICHTER GEDEON NYRT. (HU) | 2012-05-15 | — | — | US | disclosed |
| EP-1963260-B1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCESS | RICHTER GEDEON NYRT (HU) | 2010-11-03 | — | — | EP | disclosed |
| US-20090216009-A1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCESS | RICHTER GEDEON NYRT. (HU) | 2009-08-27 | — | — | US | disclosed |
| US-20090216009-A1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCESS | RICHTER GEDEON NYRT. (HU) | 2009-08-27 | — | — | US | disclosed |
| WO-2007072088-A1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCES | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216009-A1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCESS | APOB, HMGCR, PCSK9 | MGLL 855/4885LMNA 2067/4885MAPT 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.